 |
|
|
| |
Potent Antiviral Activity of S/GSK1349572, A Next Generation Integrase Inhibitor (INI), in INI-Naïve HIV-1-Infected Patients: ING111521 Protocol
|
| |
| |
Reported by Jules Levin
5th Conference on HIV Pathogenesis, Treatment and Prevention 19-22 July 2009, Cape Town South Africa
Jay Lalezari, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy,
Ivy Song, Julie Borland, Richard Stroder, ShuguangChen, Yu Lou,
Mark Underwood, Tamio Fujiwara, Stephen Piscitelli, Sherene Min
ING111521 Investigators, GlaxoSmithKline, RTP, NC, USA,
Shionogi & Co., Ltd., Osaka, Japan
|
| |
|
|
|
|
|
